Comparing gross examinations and frozen sections for surgical margins in oral cancers
Official title: Intra-operative Gross Examination Versus Frozen Section for Achievement of Adequate Margin in Patients Undergoing Surgery for Oral Cavity Squamous Cell Carcinoma: A Randomized Controlled Trial
Run by Tata Memorial Centre · NCT04809324 · Data updated 2026-11-12
This study is testing whether using frozen section analysis during surgery helps patients with oral cancer have better outcomes compared to just looking at the tissue with the naked eye.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 1206 (estimated) |
| Sponsor | Tata Memorial Centre Academic / other |
| Locations | 3 sites (Mumbai, Maharashtra and 2 other locations) |
| Status | Recruiting |
| Started | November 15, 2021 |
| Main results expected | December 2026 |
| Study ends | June 2028 |
| Registry record updated | April 11, 2025 |
| Trial ID | NCT04809324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are treatment-naïve adults over 18 years old with biopsy-proven OCSCC planned for curative surgery.
✕Probably not a fit
Patients with multifocal disease or those who have previously received treatment for oral cavity cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of gross examination versus frozen section analysis for assessing surgical margins in patients with oral cavity squamous cell carcinoma (OCSCC). It aims to determine whether the use of frozen section, which is often employed to ensure adequate margins during surgery, actually improves oncological outcomes compared to gross examination alone. The study will include treatment-naïve patients scheduled for curative surgery and will assess the cost-effectiveness of frozen section procedures in resource-limited settings. The findings could provide insights into the best practices for surgical management of OCSCC.
Why it matters
Potential benefit: If successful, this study could lead to more effective surgical practices and potentially better outcomes for patients with oral cavity cancer.
How similar studies have gone: Previous studies have shown mixed results regarding the effectiveness of frozen section analysis in improving surgical outcomes, indicating that this approach is still under investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Biopsy proven treatment naïve cases of OCSCC who are planned for curative surgery with en-bloc removal of the tumor with adequate margin 2. In detail assessment of the primary tumor is possible pre-operatively 3. Written informed consent 4. Age more than 18 years Exclusion Criteria: 1. Multifocal disease 2. Clinically evident field cancerization 3. Previous treatment for oral cavity cancer - Surgery /chemo or radiotherapy -
Where it's running
-
Tata Memorial Hospital
Mumbai, Maharashtra, India Recruiting -
ACTREC,Advanced Centre for Treatment, Research and Education in Cancer
Navi Mumbai, Raigad, India Recruiting -
Mahamana Pandit Madan Mohan Malaviya Cancer Centre
Varanasi, Uttar Pradesh, India Recruiting
Study contacts
- Principal investigator: Pankaj Chaturvedi, MS — Tata Memorial Centre
- Study coordinator: Pankaj Chaturvedi, MS
- Email: chaturvedi.pankaj@gmail.com
- Phone: +91 02224177189
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers for oral cavity cancer response to neoadjuvant immunotherapy using patient-specific tumor cultures
This will test whether a patient-specific tumor culture can predict how people with oral cavity cancer respond to pembrolizumab given before surgery.
-
Neoadjuvant chemoimmunotherapy with PD-1 blockade to reduce surgery for advanced head and neck cancer
This approach will try a short course of chemotherapy plus the PD-1 drug toripalimab before standard treatment for people with advanced head and neck cancers to shrink tumors and allow less extensive surgery or radiation.
-
Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer
This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.
-
Comparing navigation support to standard care for starting radiation therapy in head and neck cancer patients
This study is testing a new support program to help people with head and neck cancer start their radiation therapy on time compared to the usual care they receive.
-
New surgical procedure for reconstructing the oral cavity and oropharynx in cancer patients
This study is testing a new surgical method using a special tissue flap to see if it can safely help cancer patients who need reconstruction in their mouth and throat areas.
-
Comparing methods for closing the radial forearm donor site after surgery
This study is testing two different ways to close the arm after surgery for head and neck reconstruction to see which method helps patients heal better and feel happier with their results.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.